文献速递银屑病与炎症性皮肤病

银屑病达标治疗:基于BADBIR真实世界队列研究定义结局指标

Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
PubMed 文献 · Br J Dermatol · 2019-09-10

结论认为绝对PASI≤2和PGA清除/几乎清除可作为达标治疗的相关疾病终点。

要点

  • 绝对PASI≤2与PASI 90一致,可作为达标治疗的绝对终点。
  • PGA清除/几乎清除与PASI≤2在90%病例中一致。

核心结论

  • 绝对PASI≤2和PGA清除/几乎清除是银屑病达标治疗的相关疾病终点。

主要发现

  • 绝对PASI≤2与PASI 90在90%病例中一致,绝对PASI≤4与PASI 75在88%病例中一致。
  • 上述结果在评估时机、基线疾病严重度和治疗方式的亚组中稳健。
  • PGA从清除到重度,中位PASI从0(IQR 0-0,范围0-23)增至19(IQR 15-25,范围0-64)。
  • PGA清除/几乎清除与PASI≤2在90%病例中一致,PGA中重度/重度与NICE生物制剂PASI准入标准在81%病例中一致。

关键数值与推荐

  • 绝对PASI≤2对应PASI 90,绝对PASI≤4对应PASI 75。
  • PGA清除/几乎清除对应PASI≤2,PGA中重度/重度对应NICE生物制剂PASI准入标准。

临床怎么用

  • 临床可采用绝对PASI≤2作为达标治疗的疾病终点。
  • PGA清除/几乎清除可作为替代的绝对治疗终点。
  • PGA中重度/重度可作为生物制剂准入的替代标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 'treat to target' paradigm improves outcomes and reduces costs in chronic disease management but is not yet established in psoriasis. OBJECTIVES: To identify treatment targets in psoriasis using two common measures of disease activity: Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA). METHODS: Data from a multicentre longitudinal U.K. cohort of patients with psoriasis receiving systemic or biologic therapies (British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) were used to identify absolute PASI thresholds for 90% (PASI 90) and 75% (PASI 75) improvements in baseline disease activity, using receiver operating characteristic curves. The relationship between PGA (clear, almost clear, mild, moderate, moderate-severe, severe) and PASI (range 0-72) was described, and the concordance between absolute and relative definitions of response was determined. The same approach was used to establish treatment response and eligibility definitions based on PGA. RESULTS: Data from 13 422 patients were available (58% male, 91% white ethnicity, mean age 44·9 years), including over 23 000 longitudinal PASI and PGA scores. An absolute PASI ≤ 2 was concordant with PASI 90 and an absolute PASI ≤ 4 was concordant with PASI 75 in 90% and 88% of cases, respectively. These findings were robust to subgroups of timing of assessment, baseline disease severity and treatment modality. PASI and PGA were strongly correlated (Spearman's rank correlation coefficient 0·92). The median PASI increased from 0 (interquartile range 0-0, range 0-23) to 19 (interquartile range 15-25, range 0-64) for PGA clear to severe, respectively. PGA clear/almost clear was concordant with PASI ≤ 2 in 90% of cases, and PGA moderate-severe severe was concordant with the National Institute for Health and Care Excellence PASI eligibility criteria for biologics in 81% of cases. CONCLUSIONS: An absolute PASI ≤ 2 and PGA clear/almost clear represent relevant disease end points to inform treat-to-target management strategies in psoriasis. What's already known about this topic? The most commonly used relative disease activity measure in psoriasis is ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90); however, it has several limitations including dependency on a baseline severity assessment. Defining an absolute target disease activity end point in psoriasis has the potential to improve patient outcomes and reduce costs, as demonstrated by treat-to-target approaches in other chronic diseases such as hypertension and diabetes. The Physician's Global Assessment (PGA) is a popular alternative measure of psoriasis severity in daily practice; however, its utility has not been formally assessed with respect to PASI. What does this study add? An absolute PASI ≤ 2 corresponds with PASI 90 response and is a relevant disease end point for treat-to-target approaches in psoriasis. There is a strong correlation between PASI and PGA. PGA moderate-severe/severe may serve as an alternative eligibility criterion for biologics to PASI-based definitions, and PGA clear/almost clear is an appropriate alternative absolute treatment end point. What are the clinical implications of this work? Absolute PASI ≤ 2 and PGA clear/almost clear represent relevant disease end points to inform treat-to-target management strategies in psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2019. PMID: 31286471. doi:10.1111/bjd.18333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。